“Why am I still suffering?”: Experience of long-term fatigue and neurocognitive changes in oropharyngeal cancer survivors following (chemo)radiotherapy
Zsuzsanna Iyizoba-Ebozue, Florien Boele(University of Leeds), Emma Nicklin(University of Leeds), Emma Hall(Institute of Cancer Research), Sarah Brown(University of Leeds), Finbar Slevin(University of Leeds), Robin Prestwich, Matthew Lowe, Louise Murray(Leeds Teaching Hospitals NHS Trust), David Thomson(The Christie NHS Foundation Trust), James Price(The Christie NHS Foundation Trust), J. Lilley(Leeds Teaching Hospitals NHS Trust)
Technical Innovations & Patient Support in Radiation Oncology
March 8, 2024
Cited by 5
Related Papers
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912